- Joined
- 27 June 2010
- Posts
- 4,318
- Reactions
- 364
Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics.
Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally.
Hexima is based in Melbourne, Australia.
It is anticipated that HXL will list on the ASX during December 2020.
Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally.
Hexima is based in Melbourne, Australia.
It is anticipated that HXL will list on the ASX during December 2020.
Hexima Home | Hexima
Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.